ISR
Isoray, Inc. [ISR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ISR Stock Summary
In the News
ISR Financial details
Company Rating
-
Market Cap
0
Income
-24.03M
Revenue
8.17M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
66
Optionable
No
Shortable
Yes
Earnings
08 May 2023
P/E
-6.11
Forward P/E
-
PEG
-0.3
P/S
-
P/B
0.99
P/C
-
P/FCF
-
Quick Ratio
3.43
Current Ratio
3.72
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.09
EPS next Y
-
EPS next Q
-
EPS this Y
64.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-15.93%
Revenue last 5Y
12.76%
Revenue Q/Q
4.65%
EPS Q/Q
-7.05%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-15%
ROE
-21%
ROC
-0.16%
Gross Margin
20%
Oper. Margin
-234%
Profit Margin
-229%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.19-0.45
52W High
-
52W Low
-
RSI
-
Rel Volume
0.52
Avg Volume
280.83K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 280.83K
- Employee 66
- CEO Ms. Lori A. Holmes-Woods
- Headquarters Richland,WA,US
- IPO Date 2002-05-31
-
Website
https://isoray.com 
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
